By selecting the Yes, leave Amgen.com.my option you understand that you are leaving the corporate page of Amgen Malaysia and that you will be redirected to another Internet site belonging to third parties, for whose content or opinions Amgen Malaysia is not responsible and makes no representations regarding such content or its accuracy. By selecting this option and accessing linked third party sites, you understand that you do so at your own risk.
The website to which you will be redirected may be designed exclusively for residents of a particular country or countries, as advertised on that website. As a consequence, the website to which you will be directed may contain information on pharmaceutical products or indications that are not approved in Malaysia. If you reside in a country other than the one to which such website is directed, please contact your local Amgen affiliate for the correct information on products in your country of residence.
Amgen's drugs target diseases that are serious and typically have limited treatment options.
With a presence in more than 100 countries, every year we reach millions of patients around the world.
At Amgen we take advantage of the full potential of biotechnology to collaborate and provide new tools for clinical practice. In Malaysia, we focus on the following therapeutic areas:
In general medicine, Amgen is dedicated to addressing important scientific questions to advance care and improve the lives of patients with cardiovascular disease, the leading cause of morbidity and mortality worldwide.
Cardiovascular diseases, which are diseases involving the heart and blood vessels, have been the leading cause of death in Malaysia since 20051. In 2018, an average of 50 deaths a day in Malaysia were attributed to cardiovascular disease2.
Amgen is committed to raising awareness of high cholesterol and its associated risks with patients in Malaysia. We have developed educational materials, such as infographics and patient pamphlets, to explain the connection between cholesterol and heart disease.
In general medicine, Amgen is a leader in bone health with more than 20 years of osteoporosis research experience, and is committed to combating this disease to help people at high risk for fracture reduce their risk of a first and subsequent fracture.
Every three seconds, a bone breaks due to osteoporosis somewhere in the world.1 Osteoporosis is a bone disease that occurs when the body loses too much bone, makes too little bone or both.2 As a result, osteoporosis causes low bone mass and deterioration of bone3 in patients, and changes in the balance between degradation and build-up of bone tissue leads to the bone becoming increasingly fragile, raising the risk of fractures.
An osteoporosis-related fracture can be life-altering4. After an initial bone break, approximately 80% of patients remain undiagnosed and untreated.5 One way to help ensure that more people are diagnosed and treated for the disease following a fracture is to implement more outpatient post-fracture care coordination programs around the world.6,7 These programs are designed to help people who have experienced a fracture due to osteoporosis receive the appropriate information and care to help prevent future fractures before they occur.
Osteoporosis causes more than 8.9 million fractures annually worldwide8 mostly in post-menopausal women. As Malaysia’s population ages, incidence of the disease is growing9.
As a leader in osteoporosis, Amgen is working with hospitals in Asia Pacific to establish Fracture Liaison Services (FLS) to improve the diagnosis and treatment of osteoporosis. In Malaysia, the first Fracture Liaison Service was launched in 2017 at Beacon Specialist Hospital, and subsequently in 2018 at Hospital Canselor Tuanku Muhriz (HCTM), followed by Pusat Perubatan Universiti Malaya in 2020. Since its opening, it has seen a marked improvement in diagnosis and management of these patients. HCTM has been awarded a Gold award and Beacon Hospital a Silver award from the International Osteoporosis Foundation. Amgen is also a corporate partner in the Bone Health Alliance Malaysia (BHAM) that was launched in 2021.
Amgen has a portfolio of innovative products and biosimilars for the treatment of oncological and hematological diseases, such as colorectal cancer, leukemia and multiple myeloma.
Amgen developed medicines in the field of inflammation, and we are currently discovering innovative molecules to treat chronic inflammatory diseases. Some of the conditions to which we provide solutions are for autoimmune pathologies such as rheumatoid arthritis and psoriasis, which affect millions of patients in the world. Inflammation is another field in which Amgen has biosimilars approved to improve healthcare costs in chronic diseases.
For information on the drugs that are in development, we invite you to visit our pipeline.